Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
742.35
+16.63 (2.29%)
At close: Jan 21, 2025, 4:00 PM
740.00
-2.35 (-0.32%)
After-hours: Jan 21, 2025, 7:55 PM EST
Eli Lilly Revenue
Eli Lilly had revenue of $11.44B in the quarter ending September 30, 2024, with 20.43% growth. This brings the company's revenue in the last twelve months to $40.86B, up 27.41% year-over-year. In the year 2023, Eli Lilly had annual revenue of $34.12B with 19.56% growth.
Revenue (ttm)
$40.86B
Revenue Growth
+27.41%
P/S Ratio
16.36
Revenue / Employee
$950,309
Employees
43,000
Market Cap
668.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
LLY News
- 5 hours ago - Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? - CNBC
- 8 hours ago - Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound - Benzinga
- 11 hours ago - Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer's, Study Shows. What It Means for the Stocks. - Barrons
- 14 hours ago - Eli Lilly: Market Overreacted - Seeking Alpha
- 4 days ago - Ozempic, Wegovy among drugs subject to Medicare price controls - Fox Business
- 6 days ago - US FDA approves expanded use of Lilly's bowel disease drug - Reuters
- 6 days ago - FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease - PRNewsWire
- 6 days ago - Eli Lilly: Big 2025 Ahead, But Execution Risks Exist - Seeking Alpha